Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tolvaptan Clear all
Completed Not applicable Interventional Results available

TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study

NCT02538016
View directory record Official record
Conditions
Cystinuria
Interventions
Tolvaptan
Drug
Lead sponsor
Caleb Nelson
Other
Eligibility
12 Years to 29 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Sep 23, 2026, 7:24 AM EDT
Terminated Phase 4 Interventional Results available

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

NCT01890694
View directory record Official record
Conditions
Hyponatremia
Interventions
Tolvaptan, Placebo, Hepatic Encephalopathy Assessment, Quality of Life Assessment, Vital signs, Blood laboratory tests, Ascites Evaluation, Edema
Drug · Behavioral · Biological + 1 more
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

NCT00043758
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Tolvaptan in Healthy Adults

NCT01973140
View directory record Official record
Conditions
Healthy
Interventions
Tolvaptan, Hypertonic saline infusion
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Results available

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT01451827
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan MR, Tolvaptan IR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients

NCT00550459
View directory record Official record
Conditions
Hyponatremia
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Hawthorne, California • Vista, California • Colorado Springs, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT02251275
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 3 Interventional

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

NCT00071331
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
161
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

AiDing Diuresis wIth Tolvaptan (ADD-IT)

NCT02646540
View directory record Official record
Conditions
Cardiomyopathy, Congestive Heart Failure
Interventions
Tolvaptan 30 mg + IV Diuretics, Metolazone 5 mg + IV Diuretics, 2.5 times the Diuretics Dose
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 3 Interventional

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

NCT00072683
View directory record Official record
Conditions
Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
Interventions
tolvaptan, placebo matching tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure

NCT01644331
View directory record Official record
Conditions
Heart Failure, Dyspnea
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
18
States / cities
Aurora, Colorado • Atlanta, Georgia • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan in Hyponatremic Cancer Patients

NCT01199198
View directory record Official record
Conditions
Advanced Cancers
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 23, 2026, 7:24 AM EDT
Withdrawn Phase 4 Interventional

The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

NCT01663662
View directory record Official record
Conditions
Heart Failure
Interventions
Tolvaptan, placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 3 Interventional Results available

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00428948
View directory record Official record
Conditions
Polycystic Kidney Disease, Autosomal Dominant
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
1,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
30
States / cities
Mobile, Alabama • Riverside, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 4 Interventional

Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure

NCT01863511
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
loop diuretic, tolvaptan, ultrafiltration
Drug · Procedure
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 23, 2026, 7:24 AM EDT
Recruiting Phase 3 Interventional

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT04782258
View directory record Official record
Conditions
Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions
Tolvaptan Suspension, Tolvaptan Tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
28 Days to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 23, 2026, 7:24 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan for Ascites in Cirrhotic Patients

NCT01292304
View directory record Official record
Conditions
Ascites, Cirrhosis
Interventions
Tolvaptan
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 23, 2026, 7:24 AM EDT
Terminated Phase 3 Interventional Results available

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

NCT02020278
View directory record Official record
Conditions
Hyponatremia
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Sep 23, 2026, 7:24 AM EDT